IN2014MN01183A - - Google Patents
Info
- Publication number
- IN2014MN01183A IN2014MN01183A IN1183MUN2014A IN2014MN01183A IN 2014MN01183 A IN2014MN01183 A IN 2014MN01183A IN 1183MUN2014 A IN1183MUN2014 A IN 1183MUN2014A IN 2014MN01183 A IN2014MN01183 A IN 2014MN01183A
- Authority
- IN
- India
- Prior art keywords
- formula
- heteromultimers
- compounds
- mediated
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1119703.5A GB201119703D0 (en) | 2011-11-15 | 2011-11-15 | Compounds |
GBGB1214250.1A GB201214250D0 (en) | 2012-08-09 | 2012-08-09 | Compounds |
PCT/GB2012/052842 WO2013072694A1 (fr) | 2011-11-15 | 2012-11-15 | Thiéno- et furo- pyrimidines et pyridines, convenant comme inhibiteurs du canal potassium |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01183A true IN2014MN01183A (fr) | 2015-07-03 |
Family
ID=47222145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1183MUN2014 IN2014MN01183A (fr) | 2011-11-15 | 2012-11-15 |
Country Status (15)
Country | Link |
---|---|
US (2) | US9290511B2 (fr) |
EP (1) | EP2780343A1 (fr) |
JP (1) | JP2014533259A (fr) |
KR (1) | KR20140094603A (fr) |
CN (1) | CN104011054B (fr) |
AR (1) | AR090037A1 (fr) |
AU (1) | AU2012338570A1 (fr) |
BR (1) | BR112014011671A2 (fr) |
CA (1) | CA2855346A1 (fr) |
IN (1) | IN2014MN01183A (fr) |
MX (1) | MX2014005935A (fr) |
RU (1) | RU2014124101A (fr) |
TW (1) | TWI498331B (fr) |
WO (1) | WO2013072694A1 (fr) |
ZA (1) | ZA201403503B (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS57250B1 (sr) | 2013-06-06 | 2018-07-31 | Astellas Pharma Inc | Jedinjenje benzotiofena |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
RU2545758C1 (ru) * | 2014-03-20 | 2015-04-10 | Общество с ограниченной ответственностью "Алион" | Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов |
WO2016040330A1 (fr) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Composés de thiénopyrimidine et de thiénopyridine et leurs procédés d'utilisation |
EP3302057A4 (fr) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll |
TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
FR3037958B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037956B1 (fr) * | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037957B1 (fr) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR3037959B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
BR112018012914B1 (pt) | 2015-12-22 | 2023-04-18 | SHY Therapeutics LLC | Composto, uso de um composto e composição farmacêutica |
IL261606B (en) * | 2016-03-16 | 2022-09-01 | Kura Oncology Inc | Inhibitors of converted menin-mll and methods of use |
MA43823A (fr) | 2016-03-16 | 2018-11-28 | Kura Oncology Inc | Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation |
CN106727587A (zh) * | 2016-11-28 | 2017-05-31 | 李娜 | 一种治疗心律失常的药物组合物 |
EA038388B1 (ru) * | 2017-01-16 | 2021-08-19 | Кура Онколоджи, Инк. | Замещенные ингибиторы менина-mll и способы применения |
US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
IL271230B1 (en) | 2017-06-21 | 2024-02-01 | SHY Therapeutics LLC | Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases |
EP3668841A1 (fr) * | 2017-08-14 | 2020-06-24 | Acesion Pharma ApS | Benzimidazoles substitués utiles en tant qu'inhibiteurs du canal potassium |
TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
JP7254078B2 (ja) | 2017-11-27 | 2023-04-07 | ダート・ニューロサイエンス・エルエルシー | Pde1阻害剤としての置換フラノピリミジン化合物 |
CN108117556A (zh) * | 2018-01-15 | 2018-06-05 | 王山川 | 一种细胞周期检查点激酶1抑制剂的合成方法 |
KR20210106506A (ko) | 2018-12-21 | 2021-08-30 | 셀진 코포레이션 | Ripk2의 티에노피리딘 억제제 |
EP4051678A1 (fr) | 2019-10-28 | 2022-09-07 | Merck Sharp & Dohme Corp. | Inhibiteurs à petites molécules de mutant de kras g12c |
WO2021106231A1 (fr) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | Composé ayant une activité inhibitrice contre la mutation kras g12d |
WO2022194191A1 (fr) * | 2021-03-16 | 2022-09-22 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kras g12d |
JP2024511801A (ja) * | 2021-03-26 | 2024-03-15 | スミトモ ファーマ オンコロジー, インコーポレイテッド | (フロピリミジン-4-イル)ピペラジン化合物及びその使用 |
CN115006468B (zh) * | 2022-06-28 | 2023-06-06 | 西安外事学院 | 一种复方中草药生发液及制备方法 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4008726A1 (de) | 1990-03-19 | 1991-09-26 | Basf Ag | Thieno(2,3-d)pyrimidinderivate |
CA2039411A1 (fr) * | 1990-03-30 | 1991-10-01 | Ronnie Gerald Edie | Derives de la thienopyrimidine |
EP0923579A1 (fr) | 1996-08-27 | 1999-06-23 | Novartis AG | 1,2,4,6-thiatriazines s-substituees desherbantes |
WO2004011057A1 (fr) | 1998-02-07 | 2004-02-05 | Advanced Cardiovascular Systems, Inc. | Catheter de perfusion a dilatation avec enroulement support expanse |
JP2001097979A (ja) | 1999-07-28 | 2001-04-10 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および用途 |
WO2001021610A1 (fr) | 1999-09-17 | 2001-03-29 | Nissan Chemical Industries, Ltd. | Dérivé de benzopyran |
US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
DE10031585A1 (de) * | 2000-06-29 | 2002-01-10 | Merck Patent Gmbh | 2-Aminoalkyl-thieno[2,3-d]pyrimidine |
TW589305B (en) | 2001-02-14 | 2004-06-01 | Nissan Chemical Ind Ltd | 4-aminobenzopyran derivatives |
DE60206505T2 (de) | 2001-06-25 | 2006-07-06 | Nissan Chemical Industries, Ltd. | Substituierte benzopyranderivate gegen arrhytmie |
WO2003022214A2 (fr) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Composes a base de piperazine et d'homopiperazine |
AU2002333524A1 (en) * | 2001-09-11 | 2003-03-24 | Glaxosmithkline K.K. | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
US20040138238A1 (en) * | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
DE602004020070D1 (de) * | 2003-06-11 | 2010-10-07 | Xention Ltd | Thienopyrimidin-derivate als kaliumkanal-inhibitoren |
GB0315950D0 (en) * | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
US7594219B2 (en) | 2003-07-24 | 2009-09-22 | International Business Machines Corporation | Method and apparatus for monitoring compatibility of software combinations |
TWI346112B (en) | 2004-02-25 | 2011-08-01 | Nissan Chemical Ind Ltd | Benzopyran compound |
MXPA06011799A (es) * | 2004-04-12 | 2006-12-15 | Sankyo Co | Derivados de tienopiridina. |
JP4955557B2 (ja) | 2004-06-10 | 2012-06-20 | ゼンション・リミテッド | カリウムチャネル阻害剤として有効なフラノピリミジン化合物 |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
CN101084224B (zh) | 2004-10-21 | 2013-12-04 | 美国陶氏益农公司 | 具有杀真菌活性的噻吩并-嘧啶化合物 |
JP5173429B2 (ja) | 2004-12-09 | 2013-04-03 | ゼンション・リミテッド | 化合物 |
US7576212B2 (en) * | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
WO2006079916A1 (fr) | 2005-01-26 | 2006-08-03 | Pharmacia & Upjohn Company Llc | Composes de thieno [2,3-d] pyrimidine utilises comme inhibiteurs d'agregation de plaquettes induits par adp |
CA2602358A1 (fr) | 2005-03-25 | 2006-09-28 | Pharmacia & Upjohn Company Llc | Composes 4-piperazinnythieno [2,3-d] pyrimidine utilises des inhibiteurs d'agregation plaquettaire |
EP1866317A1 (fr) | 2005-03-28 | 2007-12-19 | Pharmacia & Upjohn Company LLC | Derives de 4-piperazinothieno [2, 3-d] pyrimidine en tant qu' agents inhibiteurs de l'agregation de plaquettes sanguines |
JP2008534571A (ja) | 2005-03-28 | 2008-08-28 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | 血小板凝集阻害物質としての4−ピペラジニルチエノ[2,3−d]ピリミジン化合物 |
CA2603041A1 (fr) | 2005-03-28 | 2006-10-05 | Pharmacia & Upjohn Company Llc | Composes thieno[2,3-d]pyrimidine |
US20060281768A1 (en) * | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
JP5301986B2 (ja) * | 2005-06-22 | 2013-09-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のチエノピリミジン類 |
EP1928884B1 (fr) * | 2005-09-23 | 2010-01-13 | Equispharm Co., Ltd. | Derives de 5,6-dimethyl[2,3-di]pyrimidine, leurs procede de preparation et composition pharmaceutique les comportant pour un traitement antiviral |
US20070213305A1 (en) * | 2005-11-02 | 2007-09-13 | Cytovia, Inc. | N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
EP2004656B1 (fr) * | 2006-04-07 | 2013-07-10 | Boehringer Ingelheim International GmbH | Thiénopyrimidines ayant une activité inhibitrice mnk1/mnk2 utilisées dans des compositions pharmaceutiques |
CA2654842A1 (fr) * | 2006-06-12 | 2007-12-21 | Vertex Pharmaceuticals Incorporated | Thienopyrimidines utiles en tant que modulateurs de canaux ioniques |
DE102006030236A1 (de) | 2006-06-30 | 2008-01-03 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Direktoxidationsbrennstoffzelle für den konvektionsfreien Transport des Brennstoffs und Verfahren zum Betreiben der Brennstoffzelle |
EP1947103A1 (fr) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, procédés de préparation correspondant et utilisation d'aryloxypropanolamines en tant que médicaments |
GB0713602D0 (en) | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
CN101998958B (zh) * | 2007-09-14 | 2014-03-12 | 詹森药业有限公司 | 组胺h4受体的噻吩并嘧啶和呋喃并嘧啶调节剂 |
CA2709784A1 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procede permettant de modifier la duree de vie d'organismes eucaryotes |
AR070449A1 (es) | 2008-02-22 | 2010-04-07 | Otsuka Pharma Co Ltd | Compuesto de benzodiazepina y composicion farmaceutica |
US20100227853A1 (en) | 2008-04-18 | 2010-09-09 | Trustees Of Boston College | Inhibitors of cyclic amp phosphodiesterases |
US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
CA2735361A1 (fr) * | 2008-08-26 | 2010-03-04 | Boehringer Ingelheim International Gmbh | Thienopyrimidines pour compositions pharmaceutiques |
TWI334124B (en) * | 2008-08-28 | 2010-12-01 | Au Optronics Corp | Display drive circuit for flat panel display and driving method for gate lines |
TWI389913B (zh) | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
WO2010030757A2 (fr) | 2008-09-10 | 2010-03-18 | Kalypsys Inc. | Inhibiteurs aminopyrimidine des récepteurs de l'histamine destinés au traitement d'une maladie |
WO2010033127A1 (fr) | 2008-09-22 | 2010-03-25 | Sionyx, Inc. | Pixel hybride monolithique à réponse améliorée |
CA2773131C (fr) | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions et methodes de traitement de la leucemie |
MX2012004560A (es) | 2009-10-29 | 2012-05-08 | Bristol Myers Squibb Co | Compuestos de quinuclidina como ligandos del receptor de acetilcolina nicotinico alfa-7. |
CA2788450A1 (fr) | 2009-12-30 | 2011-07-07 | Arqule, Inc. | Composes naphthalenyl-pyrimidine substitues |
TW201219401A (en) * | 2010-09-14 | 2012-05-16 | Lexicon Pharmaceuticals Inc | Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use |
CN104906103B (zh) | 2010-12-14 | 2018-05-18 | 电泳有限公司 | 酪蛋白激酶1δ(CK1δ)抑制剂 |
EP2663312B1 (fr) | 2011-01-10 | 2017-10-11 | Nimbus Iris, Inc. | Inhibiteurs d'irak et leurs utilisation |
-
2012
- 2012-11-14 AR ARP120104296A patent/AR090037A1/es unknown
- 2012-11-15 RU RU2014124101/04A patent/RU2014124101A/ru not_active Application Discontinuation
- 2012-11-15 WO PCT/GB2012/052842 patent/WO2013072694A1/fr active Application Filing
- 2012-11-15 AU AU2012338570A patent/AU2012338570A1/en not_active Abandoned
- 2012-11-15 CA CA2855346A patent/CA2855346A1/fr not_active Abandoned
- 2012-11-15 KR KR1020147015757A patent/KR20140094603A/ko not_active Application Discontinuation
- 2012-11-15 EP EP12790948.9A patent/EP2780343A1/fr not_active Withdrawn
- 2012-11-15 JP JP2014540560A patent/JP2014533259A/ja active Pending
- 2012-11-15 US US14/358,722 patent/US9290511B2/en not_active Expired - Fee Related
- 2012-11-15 IN IN1183MUN2014 patent/IN2014MN01183A/en unknown
- 2012-11-15 CN CN201280061286.3A patent/CN104011054B/zh not_active Expired - Fee Related
- 2012-11-15 MX MX2014005935A patent/MX2014005935A/es not_active Application Discontinuation
- 2012-11-15 TW TW101142693A patent/TWI498331B/zh not_active IP Right Cessation
- 2012-11-15 BR BR112014011671A patent/BR112014011671A2/pt not_active IP Right Cessation
-
2014
- 2014-05-14 ZA ZA2014/03503A patent/ZA201403503B/en unknown
-
2016
- 2016-02-05 US US15/016,846 patent/US20160152634A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104011054B (zh) | 2016-08-24 |
AR090037A1 (es) | 2014-10-15 |
WO2013072694A1 (fr) | 2013-05-23 |
RU2014124101A (ru) | 2015-12-27 |
AU2012338570A1 (en) | 2014-07-03 |
NZ626199A (en) | 2015-04-24 |
US9290511B2 (en) | 2016-03-22 |
MX2014005935A (es) | 2014-09-04 |
BR112014011671A2 (pt) | 2017-05-30 |
ZA201403503B (en) | 2016-09-28 |
EP2780343A1 (fr) | 2014-09-24 |
CA2855346A1 (fr) | 2013-05-23 |
US20160152634A1 (en) | 2016-06-02 |
JP2014533259A (ja) | 2014-12-11 |
US20140371203A1 (en) | 2014-12-18 |
TWI498331B (zh) | 2015-09-01 |
TW201326178A (zh) | 2013-07-01 |
KR20140094603A (ko) | 2014-07-30 |
CN104011054A (zh) | 2014-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01183A (fr) | ||
IN2012DN00971A (fr) | ||
PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
IN2014KN00769A (fr) | ||
TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
MD20150043A2 (ro) | Inhibitori ai histon-demetilazelor | |
AU2012214029A8 (en) | Rorgammat inhibitors | |
MX2014004766A (es) | Inhibidores de arginasa y sus aplicaciones terapeuticas. | |
MX2020001602A (es) | Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo. | |
SG10201811204RA (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
IN2014CN04907A (fr) | ||
IN2014MN00988A (fr) | ||
MY172924A (en) | Neprilysin inhibitors | |
IN2014CN04676A (fr) | ||
MX2013008192A (es) | Inhibidores de bace-2 para tratamiento de transtornos metabolicos. | |
IN2014MN00948A (fr) | ||
MX2012003644A (es) | Compuestos de 2-piridona empleados como inhibidores de la elastasa neutrofila. | |
GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
GEP20135964B (en) | Inhibitors of beta-secretase | |
EA201291099A1 (ru) | Новые иммуномодуляторные и противовоспалительные соединения | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
IN2014DN10670A (fr) | ||
JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao |